AL-ADTRAN
24.1.2023 16:13:34 CET | Business Wire | Press release
Adtran®, Inc., (NASDAQ:ADTN), the leading provider of next-generation open and disaggregated networking solutions, today launched its SDX 6330 10Gbit/s Combo PON fiber access platform, enabling service providers to rapidly and cost-effectively connect homes and businesses with fiber-based broadband. The new open and disaggregated solution offers the industry’s highest port density and is the first optical line terminal (OLT) with integrated 400Gbit/s uplinks. It will empower operators to accelerate fiber rollout and easily scale their networks to support dense urban, suburban and rural deployments. With enhanced energy efficiency, the highly compact, temperature-hardened fiber access platform will be important to meeting sustainability targets and addressing market demands for both retail and wholesale providers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230124005747/en/
Adtran’s SDX 6330 will help service providers meet subscriber demand in the most scalable and sustainable way possible. (Photo: Business Wire)
“Service providers face a tough environment as they strive to keep up with growing subscriber needs, expand coverage and meet green targets. With households and businesses accessing more and more data-hungry applications, operators need strategies in place to handle the surge in a cost-effective and sustainable way. This challenge is precisely what our third-generation fiber access platform aims to address,” said Robert Conger, SVP of technology and strategy at Adtran. “Our SDX 6330 offers the network simplicity, sustainability and scalability needed to power the Gigabit Society. That’s what makes it a compelling alternative to chassis-based architectures. It’s the solution many operators are searching for as they look to expand their market share while improving customer experience.”
The SDX 6330 is Adtran’s third generation of open and disaggregated OLT devices. With 48 ports of Combo PON in a compact and power-efficient design, it sets a new benchmark for lowering the total cost of deployment for 10Gbit/s services. Designed to deliver network simplicity and sustainability at scale, the solution offers deployment versatility and improved reach. Featuring open interfaces, it provides freedom to build best-in-class infrastructure with technology from multiple vendors, and its versatile architecture supports a wide range of network topologies and coherent optics. The SDX 6330 also helps meet corporate sustainability objectives by reducing power demand and landfill requirements.
“Our SDX 6330 is the most advanced fiber access platform in the industry, and the impact it’s about to have will be significant. By empowering service providers to reduce both the time and cost of getting people connected, we’re going to see broadband coverage increase like never before,” commented Ronan Kelly, CTO for EMEA and APAC at Adtran. “As pioneers in open and disaggregated fiber access innovation, we’ve consistently pushed boundaries, beginning with our industry-first deployments dating back to 2017. Now with our third-generation device, we’re taking density and scalability to new heights. Our SDX 6330 will transform networks into flexible, multigigabit service delivery platforms, empowering operators to stay ahead of the bandwidth consumption curve.”
About Adtran
Adtran, Inc. is a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. Adtran, Inc. is a wholly-owned subsidiary of ADTRAN Holdings, Inc. (NASDAQ:ADTN and FSE: QH9). Find more at Adtran, LinkedIn and Twitter.
Published by
Adtran, Inc.
www.adtran.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230124005747/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
